DPP4 and colonic neoplasm: Moreover, treating melanoma or colon cancer bearing mice with the FDA approved CD26 inhibitor Sitagliptin had a synergistic effect together with immunotherapy, due to improved cytotoxic T-cell recruitment to the tumours [45].